Mikkel Wandahl Pedersen

Commit Biologics has appointed Mikkel Wandahl Pedersen as CSO

Commit Biologics has announced the appointment of Mikkel Wandahl Pedersen as Chief Scientific Officer (CSO).

Mikkel is a seasoned R&D executive and scientific leader with over two decades of experience in immuno-oncology, and autoimmune disease drug discovery and development.

Most recently, he served as the CSO of Oslo-based Nykode Therapeutics, where he successfully created and executed a new research strategy, scaled the research organisation to support an expanding pipeline and spearheaded key collaborations with external pharmaceutical partners.

Prior to Nykode, Mikkel served as CSO of Symphogen (Ballerup, Denmark), where he held broad R&D responsibilities for the antibody discovery platform, lead discovery, preclinical as well as translational pharmacology, and advanced a number of products through IND studies and into the clinic.

Following the acquisition of Symphogen by Servier, he played a critical role in the integration of the R&D team.

Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: “Commit will greatly benefit from Mikkel’s exceptional leadership and deep scientific expertise. His years of experience in antibody-based drug discovery and his proven track record of building highly productive R&D teams will be invaluable as we move towards drug candidate nomination.”

Mikkel enthused: “Commit’s BiCE-based approach, harnessing the power of the complement system, has huge potential for tackling serious diseases, including cancer and autoimmune diseases. We have the opportunity to create a unique approach to developing meaningful therapies for patients, which is one of the main reasons I have joined this exciting company.”